BioSpace News Archive

Taysha Gene Therapies, Inc. today announced that it has been granted orphan drug designation from the European Commission for TSHA-120, an intrathecally dosed AAV9 gene therapy currently in ongoing clinical evaluation for the treatment of giant axonal neuropathy (GAN).

XORTX Therapeutics Inc. is pleased to announce that dosing of human subjects has been initiated in the XRX-OXY-101 bridging pharmacokinetics study (“PK Study”).

Rhythm Pharmaceuticals, Inc. today reported financial results and provided a business update for the first quarter ended March 31, 2022.

Apellis Pharmaceuticals, Inc. announced today that renowned hematologist Peter Hillmen, MB ChB, PhD, will join the company as head of hematology engagement, effective May 23, 2022.

Tarsus Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 5,600,000 shares of common stock at a public offering price of $13.50 per share, which represents $75.6 million of common stock, before underwriting discounts and commissions.

rBIO, an early-stage synthetic biology company focused on reducing the cost of increasingly costly biologic therapies, announced refinement of its bacteria-based production of insulin.

Stryker (NYSE: SYK) announced today the publication of results from a multicenter, single-blinded, randomized controlled trial comparing Stryker’s InSpace implant with partial repair for the treatment of full-thickness massive irreparable rotator cuff tears (MIRCTs) in the Journal of Bone and Joint Surgery (JBJS).

Bausch + Lomb today announced that data from the second pivotal Phase 3 trial (MOJAVE) of investigational treatment NOV03.

Omega Therapeutics will present preclinical data on its novel Omega Epigenomic Controller (OEC) to regulate expression of the c-Myc (MYC) oncogene via epigenomic programming in models of NSCLC in a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, taking place in Washington, D.C., May 16-19, 2022.

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2022.